Revenue increases by 5.7% in FY 2009/2010 — EBIT margin climbs to 12.8% — New company program sets targets until 2015

The medical technology provider Carl Zeiss Meditec closed its financial year (ending 30 September 2010) on a high and closes with record results. Revenue and profit significantly exceeded previous year's figures and market expectations. The RACE 2010 corporate program has been successfully concluded.

 

“With our products and solutions for ophthalmology and microsurgery we aim to actively promote and shape medical progress — and the figures prove that we have been successful,” explains Dr Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

The key figures at a glance

Carl Zeiss Meditec generated consolidated revenue of EUR 677 million in financial year 2009/2010, compared to EUR 640 million the previous year. This represents an increase of 5.7%. Microsurgery SBU grew by 7%. The Surgical Ophthalmology SBU, driven by the successful sales of innovative intraocular lenses, grew by 8%.

 

By region, the Asian/Pacific region grew fastest at 16.6%. The strategy of becoming involved in growth markets such as India and China at an early stage and maintaining a presence for local customers has proved to be right.

Earnings before interest and tax (EBIT) increased by 14% in the reporting period to EUR 86.7 million (previous year: EUR 76.1 million). The EBIT margin increased by 0.9 percentage points to 12.8%. Carl Zeiss Meditec thus posts a record result for the year.

Investments in research and development of EUR 72.4 million (+ EUR 9 million) were at the highest level ever. The company is therewith stressing the importance of innovations for the expansion of its market position and its contribution to future sustained growth of the enterprise.

At the Annual General Meeting, the company will propose a dividend of EUR 0.55 per share consisting of a regular dividend of EUR 0.22 per share and a one-off special dividend of EUR 0.33 per share. The successful financial year 2009/2010 is confirmation that Carl Zeiss Meditec has taken the right path towards sustained growth, in which the company's shareholders are to participate.


Dr Ludwin Monz: “In addition to a clear strategy, this success is above all attributable to the untiring efforts of our committed employees. With a clear focus on the customer, it is they who are responsible for promoting the future of medical technology.”

Investments in research and development of EUR 72.4 million (+ EUR 9 million) were at the highest level ever. The company is therewith stressing the importance of innovations for the expansion of its market position and its contribution to future sustained growth of the enterprise.
 

At the Annual General Meeting, the company will propose a dividend of EUR 0.55 per share consisting of a regular dividend of EUR 0.22 per share and a one-off special dividend of EUR 0.33 per share. The successful financial year 2009/2010 is confirmation that Carl Zeiss Meditec has taken the right path towards sustained growth, in which the company's shareholders are to participate.


Dr Ludwin Monz: “In addition to a clear strategy, this success is above all attributable to the untiring efforts of our committed employees. With a clear focus on the customer, it is they who are responsible for promoting the future of medical technology.”